AEZS-136

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameAEZS-136
Drug Alias Namedual PI3K/ERK inhibitors (AEterna Zentaris)dual PI3K and Erk inhibitor (AEterna Zentaris)D-87503AEZS-136AEZS-132
ClassificationSmall molecules
Mechanisms of ActionExtracellular-signal-regulated kinase1 inhibitorsAnticancer protein kinase inhibitorsPI3-kinase class I inhibitors +[6] 
TargetsPI3-kinase class IExtracellular-signal-regulated kinase 2Extracellular-signal-regulated kinase1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCOSCIENS Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCOSCIENS Biopharma Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A